G1 Therapeutics Inc (NASDAQ: GTHX) is 8.85% higher on its value in year-to-date trading and has touched a low of $1.08 and a high of $5.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GTHX stock was last observed hovering at around $3.33 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $3.32, the stock is 0.13% and 0.34% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.72 million and changing -0.30% at the moment leaves the stock 41.70% off its SMA200. GTHX registered -8.29% loss for a year compared to 6-month gain of 89.71%. The firm has a 50-day simple moving average (SMA 50) of $1.72 and a 200-day simple moving average (SMA200) of -$2.36.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -12.40% loss in the last 1 month and extending the period to 3 months gives it a 96.45%, and is 54.42% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.42% over the week and 11.85% over the month.
G1 Therapeutics Inc (GTHX) has around 170 employees, a market worth around $172.11M and $82.51M in sales. Profit margin for the company is -58.13%. Distance from 52-week low is 207.41% and -33.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.48%).
G1 Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.23 with sales reaching $14.96M over the same period.The EPS is expected to grow by 23.30% this year, but quarterly earnings will post -16.70% year-over-year. Quarterly sales are estimated to grow 15.60% in year-over-year returns.
102 institutions hold shares in G1 Therapeutics Inc (GTHX), with institutional investors hold 34.26% of the company’s shares. The shares outstanding are 51.50M, and float is at 42.20M with Short Float at 7.88%. Institutions hold 30.39% of the Float.
The top institutional shareholder in the company is Fisher Asset Management, LLC with over 2.54 million shares valued at $6.33 million. The investor’s holdings represent 4.91% of the GTHX Shares outstanding. As of Jun 29, 2023, the second largest holder is JP Morgan Chase & Company with 2.12 million shares valued at $5.27 million to account for 4.09% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 1.95 million shares representing 3.77% and valued at over $4.86 million, while Blackrock Inc. holds 2.29% of the shares totaling 1.19 million with a market value of $2.95 million.
G1 Therapeutics Inc (GTHX) Insider Activity
A total of 0 insider transactions have happened at G1 Therapeutics Inc (GTHX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Malik Rajesh, the company’s Chief Medical Officer. SEC filings show that Malik Rajesh sold 28,600 shares of the company’s common stock on Feb 12 at a price of $4.62 per share for a total of $0.13 million. Following the sale, the insider now owns 0.17 million shares.
G1 Therapeutics Inc disclosed in a document filed with the SEC on Jan 04 that MURDOCK TERRY L (Chief Operating Officer) sold a total of 721 shares of the company’s common stock. The trade occurred on Jan 04 and was made at $2.94 per share for $2121.0. Following the transaction, the insider now directly holds 0.1 million shares of the GTHX stock.
Still, SEC filings show that on Jan 04, Avagliano Mark (Chief Business Officer) disposed off 721 shares at an average price of $2.94 for $2121.0. The insider now directly holds 117,834 shares of G1 Therapeutics Inc (GTHX).
G1 Therapeutics Inc (GTHX): Who are the competitors?
One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 139.23% up over the past 12 months.Novartis AG (NOVN) lies in the list of competitors of the G1 Therapeutics Inc and is 18.31% higher over the same period from GTHXRoche Holding AG Akt (RO) is -16.13% down on the 1-year trading charts.
